HomeScienceHydroxychloroquine code, a large analysis claimed. Only until it was downloaded
Hydroxychloroquine code, a large analysis claimed. Only until it was downloaded
October 30, 2021
According to an analysis of data from thousands of patients in the course of the disease covid-19 code, the large-scale study of hydroxychloroquine, which was often used in the Czech Republic, was based on data from the rest of the world. The authors withdrew the study after a few weeks.
Update 2: Those of the authors of the study of The Lancet magazine had the study withdrawn (their letter in PDF). The company that was supposed to collect the data for the study, Surgisphere, refused to provide for an independent audit and control of the data from which the study was based on a drain, thus violating the contracts with the medical facilities from which it obtained the data. According to their own words, those changed cars cannot guarantee the quality of the study.
Staen didn’t drink from the blue sky. Data from the study were questioned by a number of scientists on the blogs, social networks, and on May 28, an open letter appeared calling for a result check, which was signed by about two hundred scientists. The Lancet magazine added to the study a warning that the vn gardens appeared.
At the end of June, the WHO thus resumed the course of studies, which it suspended after the publication. Thus, in her large trials, there were no indications that hydroxychloroquine and chloroquine were associated with mortality, as suggested by the Lancet study.
Let us add that the research is based on evidence of a positive effect of hydroxychloroquine against covid-19 errors. This June, for example, published a study in the NEJM magazine examining preventive (prophylactic) scams in people who were in contact with them, in whom the infection was proven. There was no statistically observable difference between sweat in the lk groups and in the placebo groups.
We will bring more details in the new article. The original text was left unchanged.
Update 1: The World Health Organization (WHO) clinical trial of hydroxychloroquine has suspended the placement of another patient in the Solidarity study due to an analysis from the Lancet magazine, which is the subject of the text. The group wants to make sure that the data collected so far does not indicate that it would harm patients. Depending on the result, the study will be continued, or it may be recommended to abort it.
Hydroxychloroquine is probably the strongest word we have learned from the new coronavirus epidemic. The drug, which was originally used against malaria, was often mentioned as a tool in the fight against covid-19. India, which is today the largest producer of unpatented livestock, has been intensively developed, according to President Donald Trump.
However, nothing is so far clear. The use of hydroxychloroquine is being tested in several large clinical studies, and in the Czech Republic, for example, a large number of patients who were hospitalized with covid-19 received it. According to the Ministry of Health, the product was used only, according to official data, 661 out of a total of 1,300 hospitalized in the Czech Republic, in the form of Plaquenil, which contains hydroxychloroquine as another substance.
A graph from the press conference on May 22, 2020, showing how the drugs were used in hospitalized patients with covid-19. Hydroxychloroquine is abbreviated HCQ, chloroquoin is abbreviated CQ. The table does not show the total number of hospitalized with covid-19 in R, according to the data presented at the same press conference, there were 1298.
The estimate was based primarily on the incidence of coronavirus in the test tube, ie in beeches grown in the laboratory. Such results are very often, in fact, faded from these relnch. therefore, since the arrest, it was an interesting but uncertain possibility. And the actual results in clinical practice are still more controversial, in some cases the effect may be positive, in others it seems to be possible for patients to benefit.
We do not have a definitive answer, but the chances that the antimalarial could indeed represent other help – at least in the event of an outbreak of the disease – are declining. The largest public analysis, published on May 22 in The Lancet (here in PDF), also contributed to this.
The authors followed the course of the disease in thousands of patients hospitalized around the world (with the predominance of North America). According to the analysis, hydroxychloroquine (and thus related substances) did not have a positive effect on the study group. On the contrary, the mortality in the groups was a bit small and you were also at risk of other observed complications. Let us repeat that in the groups the people were hospitalized, ie the people in general during the illness. Thus, the results cannot verify that the drug does not change during the early morning.
Nen to ideln
Let’s not imagine the animals in more detail, one very important point: the results of the new study have one weakness. This is the so-called observan study. The authors only collected the results from a patient who was being treated by someone else, and could not influence, for example, which patients received, how much they received or, depending on how much of the disease they received (he had a side note: everyone in the study included patients received hydroxychloroquine and another test within 48 hours of a positive test, but could still be in another stage of disease development).
The diversity of the data was not a problem: the authors of the analysis collected data from 671 hospitals on six continents. There will be differences between them, which the results will blur. The authors tried to take the differences into account as best they could, so they deducted from the result things like overweight, high blood pressure, age, ethnicity and other factors. However, this is not a 100% bulletproof process. There may be something wrong and there may be some risk factors.
It would be much better if it was a time-long clinical study, in which the authors could much better and more accurately select a single group for the experiment, be able to monitor the course of disease and disease and regularly compare it with some very similar group, which . Such a clinical study of hydroxychloroquine against covid-19 is currently being conducted (two are also registered in R), but we do not have the result of a large, time-tested test of this type. That’s why we take a big study from The Lancet.
The authors collected data from approximately 96,000 patients who were hospitalized with a positive test for the presence of SARS-CoV-2 virus in the body (ie, a PCR test). They were divided into five groups: by far the largest was the control group, which did not receive hydroxychloroquine or related chloroquine. There were about 81 thousand people in t. Of course, lkai is in some way lily, and undoubtedly in somewhat different ways. This is given by the weakness of the analysis: the control group was very diverse.
The remaining three groups received either hydroxychloroquine alone (3,016 patients) and chloroquine (1,868 patients). Or the combination of these preparations with the antibiotics that were used (in combination with hydroxychloroquine it was 6,221 patients, with chloroquine 3783).
There was not much difference in the results between the lk groups. All increased the risk of death in patients by about 25 and 50 percent. You can imagine that in a large control group of this study, the probability of death was about 9.3 percent, according to the analysis, it should increase to about 11-14 percent.
Various factors affecting the death of patients included in an observational study investigating the effects of hydroxychloroquine and related substances. The result for these products is highlighted in the box at the bottom of the page. As can be seen, in all cases the result is to the right of the centers of the axis, and in all cases it is therefore a factor that increases the risk of death.
mortality in the groups that received them was you (about 16 to 24 percent), but it was the bottom of the dark, in which patients were more at risk of the disease. More people with overweight, diabetes, heart sweats, etc. When the authors deducted these risk factors, they changed their risk by about a half and a half.
Pina is unclear. Although the authors recorded more heart attacks in patients in the various groups, their analysis could not accurately determine whether it was the cause of excessive death at first. This is a known and proven time in addition to other investigated products, it is also a reasonable estimate, but it is certainly not proven at this time. For example, a drug acting on the function of the immune system could play a role.
Changed procedures are now the subject of clinical trials, including two evaluations approved in the Czech Republic (information on the first and second studies on the SZ pages). Their result is a bag unknown. Even in the light of this large observan study, it would undoubtedly be surprising if the studies provided unequivocally positive results.
However, this cannot be ruled out, because otherwise it will fly to a number of circumstances (two, moment of stimulus, etc.). In particular, at least for the time being, they did not provide significant negative results, as patients are obliged to stop similar tests if the preliminary results indicate that patients have an obvious code.
Number of positive SARS-Cov-2 virus tests in R per day since late 2020